Published in Cancer Weekly, February 14th, 2006
Nathanael Gray, of the Genomics Institute of the Novartis Foundation, and colleagues reported their finding in the February 2006 issue of Nature Chemical Biology.
CML is a common form of leukemia that is typically characterized by two genes, BCR and ABL1, connecting when they should be separate. The resulting fusion protein causes cellular signaling pathways to be on when they should be off and contributes to the development of CML.
CML patients are developing resistance to the current clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.